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Letters to the Editor
In Reply
Overmanetal. [1]addressedseveralcritical issues inourprospective
observational study of the FOLFOX4 regimen in patients with
pseudomyxoma peritonei (PMP) of appendiceal origin [2].
The first point is the pathologic classification used in our
study [2]. We acknowledge that classification of PMP and
the associated mucinous appendiceal neoplasms has been
hindered by controversy and confusion. As referenced in the
text, we categorized our PMP cases into low and high grade
based on the fourth edition of the World Health Organization
classification [3]. Such a classification basically retainsMisdraji
categorization of primary appendiceal tumors into low-grade
appendiceal mucinous neoplasms (typically associatedwith low-
gradePMP), andmucinousadenocarcinoma (typically associated
with high-grade PMP) [4]. Nevertheless, discordance in the
degreeof atypiabetweenappendiceal andperitoneal lesionshas
beenreported inthe literature [5].Over thepast2years, themain
PMP management centers, including our institution, have been
involved inan internationalDelphi consensusprocesstoestablish
common nomenclature and classification for this rare disease.
Preliminary results were presented at the 9th International
Congress on Peritoneal Surface Malignancies (October 9–11,
2014; Amsterdam,The Netherlands).
Second, Overman et al. raised the question of whether
repeated cytoreductive surgery with or without hyperthermic
intraperitoneal chemotherapy could have influenced out-
comes such as progression-free survival and, above all, overall
survival [1]. Based on our risk-benefit profile assessment of
individual patients, their tumor loads, and disease biological
aggressiveness, we chose to register in this studyonly patients
for whom repeated surgical debulking was considered tech-
nically difficult or biologically useless [2]. In fact, none of the
patients in our study underwent surgery twice.
The third point is the presence of 7 cases with.20% disease
growth at 3 months, which may seem unusual in an usually indo-
lentdiseasesuchasPMP. Itmustbenotedthatourseries included
eight patients with high-grade PMP [2]. In addition, it is well
known that histologically indolent PMP may show clinically
aggressive and rapidly lethal behaviors [6]. We observed median
overall survival of 26.2 months in our patients. This is comparable
with the median of 23.9 months obtained by modern highly ef-
fectivesystemictherapies incolorectalperitonealcarcinomatosis,
a disease traditionally consideredmore aggressive than PMP [7].
The last andmost relevant issue is thedifficulty in quantifying
disease response using current radiological tools and Response
Evaluation Criteria In Solid Tumors (RECIST).We agree that this is
a potential limitation of our study [2] and in any other study
involving PMP because of its diffuse nature, with abundant
collection of mucinous material and a scant cellular component
[8]. Overman et al. hypothesize that changes in disease volume
seen in four patients of our series may be explained by
mechanisms other than treatment effect [1]; however, this is
merelyspeculative.Furthermore,4of20patients inourserieshad
partial response, and 4 of 9 with stable disease showed
a significantdecrease in serumtumormarkers, possibly reflecting
treatment effect on the cellular component of the disease.
The trial (NCT01946854) [2] and the modified peritoneal
RECIST measurement proposed by Overman et al. [1] are
scientifically sound; however, the study design, which will
hopefully clarify whether chemotherapy is active in PMP, cannot
provide information on which drugs or combinations are active.
We are currently conducting molecular and genetic research to
identify new targets for therapeutic interventions and predictive
biomarkers in PMP.The final aim of these studies is to rationalize
the choice of treatment, which remains an unmet clinical need.
DARIO BARATTI
SHIGEKI KUSAMURA
Department of Surgical Oncology, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
CLAUDIA MAGGI
FILIPPO DE BRAUD
Department of Medical Oncology, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
MARCELLO DERACO
Department of Surgical Oncology, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
MARIA DI BARTOLOMEO
FILIPPO PIETRANTONIO
Department of Medical Oncology, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
Disclosures
FilippodeBraud:Novartis , Roche,GlaxoSmithKline,Bristol-MyersSquibb,
NervianoMedical Sciences,Merck (RF);Novartis , Roche,GlaxoSmithKline,
Bristol-Myers Squibb, Merck (H). The other authors indicated no financial
relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert
testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/
inventor/patent holder; (SAB) Scientific advisory board
REFERENCES
1. Overman MJ, Eng C, Matamoros A et al. Challenges of efficacy
assessments in pseudomyxoma peritonea. The Oncologist 2015;20:335–336.
2. Pietrantonio F, Maggi C, Fanetti G et al. FOLFOX-4 chemotherapy for
patients with unresectable or relapsed peritoneal pseudomyxoma. The
Oncologist 2014;19:845–850.
3. CarrNJ, Sobin LH. Adenocarcinomaof theappendix. In: Bosman FT, Carneiro
F, Hruban RH et al., eds. WHO Classification of Tumors of the Digestive System.
Vol. 3. Lyon, France: International Agency for Research on Cancer, 2010:93–102.
4. Misdraji J,YantissRK,Graeme-CookFMetal.Appendicealmucinousneoplasms:
A clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089–1103.
5. CarrNJ, Finch J, Ilesley ICetal. Pathologyandprognosis inpseudomyxoma
peritonei: A review of 274 cases. J Clin Pathol 2012;65:919–923.
6. Mohamed F, Gething S, Haiba M et al. Clinically aggressive pseudomyxoma
peritonei: A variant of ahistologically indolentprocess. J SurgOncol 2004;86:10–15.
7. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus
intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcino-
matosis of colorectal origin. J Clin Oncol 2009;27:681–685.
8. FarquharsonAL, PraneshN,WithamGetal. Aphase II studyevaluating the
use of concurrent mitomycin C and capecitabine in patients with advanced
unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591–596.
http://dx.doi.org/10.1634/theoncologist.2014-423
TheOncologist 2015;20:e5 www.TheOncologist.com ©AlphaMed Press 2015
 by guest on O
ctober 30, 2019
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
